Israel - Hebräisch - Ministry of Health

pfizer pharmaceuticals israel ltd - tofacitinib - טבליה - tofacitinib 10 mg - tofacitinib

Israel - Hebräisch - Ministry of Health

pfizer pharmaceuticals israel ltd - tofacitinib as citrate - טבליות עם שחרור נרחב - tofacitinib as citrate 11 mg - tofacitinib

Israel - Hebräisch - Ministry of Health

biotis ltd - prucalopride as succinate - טבליות מצופות פילם - prucalopride as succinate 1 mg - prucalopride - prucalopride - resolor is indicated for symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief

Israel - Hebräisch - Ministry of Health

biotis ltd - prucalopride as succinate - טבליות מצופות פילם - prucalopride as succinate 2 mg - prucalopride - prucalopride - resolor is indicated for symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief

Israel - Hebräisch - Ministry of Health

sanofi israel ltd - clopidogrel as hydrogen sulfate - טבליות מצופות פילם - clopidogrel as hydrogen sulfate 75 mg - clopidogrel - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid

Israel - Hebräisch - Ministry of Health

dexcel pharma technologies ltd - clopidogrel as besylate - טבליות מצופות פילם - clopidogrel as besylate 75 mg - clopidogrel - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows:• recent mi, recent stroke or established peripheral arterial disease: patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. for patients with a history of recent myocardial infarction (mi), recent stroke or established peripheral arterial disease, clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new mi (fatal or not) and other vascular death.• acute coronary syndrome: for patients with acute coronary syndrome (non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction), in combination with asa in medically treated patients eligible for thrombolytic therapy, and those who are to be managed with percutaneous coronary intervention (with or without stent) or cabg clopi

Israel - Hebräisch - Ministry of Health

novo nordisk ltd., israel - estradiol as hemihydrate; norethisterone acetate - טבליות מצופות פילם - estradiol as hemihydrate 1 mg; norethisterone acetate 1 mg - estradiol, combinations - estradiol, combinations - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women with an intact uterus. prevention of osteoporosis in postmenopausal women at high risk of future fractures, who are tolerant of , or contraindicated for other medicinal products approved for the prevention of osteoporosis.

Israel - Hebräisch - Ministry of Health

novo nordisk ltd., israel - estradiol as hemihydrate; norethisterone acetate - טבליות מצופות פילם - estradiol as hemihydrate 0.5 mg; norethisterone acetate 0.1 mg - estradiol, combinations - estradiol, combinations - eviana is indicated for women who have a uterus for the: treatment of moderate to severe vasomotor symptoms associated with menopause. prevention of postmenopausal osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medications should be carefully considered.

Israel - Hebräisch - Ministry of Health

cts ltd - tamsulosin hydrochloride - modified release capsules - tamsulosin hydrochloride 0.4 mg - treatment of functional symptoms of benign prostatic hyperplasia (bph).

Israel - Hebräisch - Ministry of Health

glaxo smith kline (israel) ltd - abacavir as sulfate - טבליות מצופות פילם - abacavir as sulfate 300 mg - abacavir - abacavir - ziagen is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infected adults and children.